I have read with great interest the report of the ARCHER 1050 trial by Li-Yong Wu and colleagues.¹ The findings showed the superiority of dacomitinib over gefitinib in terms of progression-free survival in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) with the common EGFR mutation. The results were initially presented at the 2017 ASCO Annual Meeting and, at that time, it was the first time that a second-generation EGFR tyrosine kinase inhibitor (TKI) showed a clear and clinically significant improvement in terms of progression-free survival (14·7 months [95% CI 11·1–16·6] with dacomitinib vs 9·2 months [9·1–11·0] with gefitinib).

中文翻译：

---

达科替尼在NSCLC中的临床试验效果不显着

我非常感兴趣地阅读了吴立勇及其同事关于ARCHER 1050试验的报告。¹研究结果表明，在具有共同EGFR突变的IIIB / IV期非小细胞肺癌（NSCLC）患者的无进展生存期方面，达科替尼优于吉非替尼。结果最初提交于2017 ASCO年会，当时是第二代EGFR酪氨酸激酶抑制剂（TKI）首次在无进展生存方面显示出明显且临床上的显着改善（14 ·7个月[95％CI 11·1-16·6] dacomitinib VS 9·2个月[9·1-11·0]吉非替尼）。